There is no registration fee for this event. However, preregistration is advised for the in-person meeting in Orlando as seating is limited. See Location tab for instructions on how to secure hotel accommodations.

---

  Faculty

This activity is supported by educational grants from ADC Therapeutics, Daiichi Sankyo Inc, Gilead Sciences Inc, Hologic Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Regeneron Pharmaceuticals Inc, and Stemline Therapeutics Inc.

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Hormone Receptor (HR)-Positive Breast Cancer
Upon completion of this activity, participants should be able to

• Evaluate the results of genomic assays and other patient- and treatment-related factors to personalize adjuvant systemic therapy for localized HR-positive, HER2-negative breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents may be appropriate.
• Review available research findings documenting the correlation between the presence of various biomarkers (eg, PIK3CA/AKT1/PTEN alterations, ESR1 mutations) and response to specific therapies, and develop optimal testing algorithms for patients with HR-positive metastatic breast cancer (mBC).
• Appraise published efficacy and safety data from randomized clinical trials evaluating CDK4/6 inhibitors for HR-positive mBC in order to appropriately counsel patients regarding the optimal use of these agents.
• Understand the mechanism of action of, published research findings with and current and future clinical role of oral selective estrogen receptor degraders for patients with HR-positive mBC harboring ESR1 mutations.
• Interrogate published Phase III research findings documenting the efficacy of AKT inhibitors in patients with progressive HR-positive mBC to determine the current clinical applicability of this approach.
• Define endocrine resistance in HR-positive mBC, and integrate available nonhormonal therapies into the care of patients with relapsed/refractory (R/R) disease.
• Appreciate the incidence, characteristics and clinical relevance of HER2-low or HER2-ultralow mBC, and understand available research findings with HER2-directed antibody-drug conjugates (ADCs) for these patients.
• Interrogate published Phase III research findings documenting the efficacy of TROP2-directed ADCs in patients with HR-positive mBC to determine the current and future clinical applicability of these approaches.

Prostate Cancer
Upon completion of this activity, participants should be able to

• Infer how various clinical and biological factors affect the risk of prostate cancer recurrence after local treatment, and design appropriate care plans for patients with consideration of the potential benefits and risks of new and established forms of hormonal therapy.
• Appraise published research findings with systemic treatment approaches for patients with biochemical recurrence after local therapy for prostate cancer, and as appropriate, provide counsel regarding the potential benefits of FDA-approved options.
• Evaluate the published research database supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic prostate cancer, and apply this information in the discussion of nonresearch treatment options for patients.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into current clinical management algorithms.
• Establish an evidence-based approach to the selection and sequencing of available therapeutic options for patients with metastatic castration-resistant prostate cancer (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biological factors.
• Assess the available research database supporting the use of PARP inhibitors as monotherapy or in combination with androgen receptor pathway inhibitors for patients with mCRPC harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway in patients with metastatic prostate cancer, and evaluate available data with and ongoing research studies of novel AKT inhibitors.
• Appreciate available Phase III data documenting the efficacy of PSMA-targeted radioligand therapy in patients with PSMA-positive mCRPC, and consider the current and future clinical role of this strategy.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

Lung Cancer
Upon completion of this activity, participants should be able to

• Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant, adjuvant or consolidation therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
• Review published research documenting the efficacy of EGFR-directed treatment in localized, locally advanced and metastatic NSCLC with an EGFR tumor mutation, and apply this information in the care of appropriately selected patients.
• Communicate the efficacy and safety of approved ALK inhibitors to appropriately selected patients with localized and metastatic NSCLC.
• Recollect other oncogenic pathways (eg, ROS1, RET, MET, HER2, KRAS, NTRK) mediating the pathogenesis of NSCLC in unique patient subsets, and recall published data with commercially available and experimental agents exploiting these targets.
• Consider recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic therapies for metastatic NSCLC, and discern how these approaches can be employed in the management of this disease.
• Develop a long-term care plan for patients with progressive NSCLC, considering exposure to prior systemic therapy, performance status and personal goals of treatment.
• Design an optimal approach to the long-term clinical care of patients with small cell lung cancer, considering available research findings and the implications of age, symptomatology, disease stage and other clinical factors.
• Reflect on investigational agents and strategies currently in testing for lung cancer, and as applicable, refer eligible patients for clinical trial participation.

Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Upon completion of this activity, participants should be able to

• Individualize the selection of systemic therapy for patients with newly diagnosed chronic lymphocytic leukemia (CLL), considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and individual preferences for time-limited or continuous treatment.
• Appraise available and emerging data documenting the efficacy and tolerability of Bruton tyrosine kinase inhibitors in the care of patients with CLL, and consider the implications of these findings for clinical decision-making.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with R/R CLL.
• Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and future utility of those agents in clinical practice.
• Understand published research data informing the selection, sequencing or combining of available therapeutic agents in the nonresearch care of patients with previously untreated or R/R follicular lymphoma (FL).
• Consider patient age, performance status and other clinical and biological factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
• Assess available clinical trial findings informing the use of CD19-directed chimeric antigen receptor (CAR) T-cell therapy for R/R DLBCL, FL, MCL and CLL, and counsel appropriately selected patients regarding the potential benefits of this therapeutic strategy.
• Evaluate the mechanism of action of and available trial findings with bispecific antibodies targeting CD20 x CD3 in patients with FL and DLBCL, and determine the role of these agents in current clinical management.
• Recall new data with agents and strategies currently under investigation for CLL and various NHL subtypes, and discuss ongoing trial opportunities with eligible patients.

Multiple Myeloma (MM)
Upon completion of this activity, participants should be able to

• Customize the selection of first-line therapy for newly diagnosed MM, considering new clinical research findings, patient- and disease-related factors, including cytogenetic profile, and fitness for stem cell transplantation.
• Appreciate trial data informing the front-line use of CD38-directed monoclonal antibody therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into clinical management.
• Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with R/R MM.
• Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with FDA-approved novel therapies to facilitate their integration into MM management algorithms.
• Evaluate the biological rationale for and published and emerging research information with CAR T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy for MM, and identify patients for whom treatment with this novel approach should be considered or recommended.
• Assess available findings with BCMA- and non-BCMA-directed bispecific antibodies for MM, and recognize patients for whom treatment with one of these novel agents would be appropriate.
• Review recently presented research findings establishing the efficacy of BCMA-directed ADC therapy, and recognize the potential clinical role of this form of treatment.
• Recall the mechanisms of action of and available research data with novel investigational agents and strategies for MM, and appropriately counsel patients about participation in relevant clinical trials.

CE Credit
CME, ABIM MOC, ABS and ACPE credit links will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 5 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Education provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.05 CEU (5 contact hours) of continuing education credit. To receive 5 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statements
This educational activity for 5 contact hours is provided by Research To Practice.
This activity is awarded 5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This program will be submitted for ONCC/ILNA certification.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Goldberg — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Regeneron Pharmaceuticals Inc, Summit Therapeutics; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Mirati Therapeutics Inc; Data and Safety Monitoring Board/Committee: Daiichi Sankyo Inc. Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, Kite, A Gilead Company, Lilly, Merck, Novartis, Pfizer Inc, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Lilly, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeiGene Ltd, Roche Laboratories Inc. Dr Kumar — Advisory Committees (with No Personal Payments): AbbVie Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc; Consulting Agreements (with No Personal Payments): AbbVie Inc, Amgen Inc, Arcellx, BeiGene Ltd, Bristol Myers Squibb, CARsgen Therapeutics, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Moderna, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Advisory Committee (with Personal Payment): BD Biosciences; Contracted Research (Clinical Trial Support to Institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, CARsgen Therapeutics, Genentech, a member of the Roche Group, Gracell Biotechnologies, GSK, Janssen Biotech Inc, Oricell Therapeutics, Sanofi, Takeda Pharmaceuticals USA Inc, Telo Genomics; Data and Safety Monitoring Boards/Committees: AbbVie Inc, Bristol Myers Squibb, Janssen Biotech Inc, Sanofi; Nonrelevant Financial Relationship: CVS Caremark. Dr O’Shaughnessy — Advisory Committees and Consulting Agreements: Agendia Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BioNTech SE, Byondis, Caris Life Sciences, Daiichi Sankyo Inc, DAVA Oncology, Eisai Inc, Exact Sciences Corporation, Fishawack Health, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Menarini Group, Merck, Mersana Therapeutics Inc, Novartis, Ontada, Pfizer Inc, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Tempus, Veru Inc. Dr Raje — Advisory Committees: Caribou Biosciences Inc, Immuneel Therapeutics; Consulting Agreements: AbbVie Inc, Amgen Inc, Bristol Myers Squibb, Janssen Biotech Inc, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: bluebird bio. Dr Sabari — Advisory Committees and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc. Dr Matthew Smith — Advisory Committees and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Arvinas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc. Dr Sonali M Smith — Consulting Agreements: Genmab US Inc, Ono Pharmaceutical Co Ltd, Regeneron Pharmaceuticals Inc; Contracted Research: Ipsen Biopharmaceuticals Inc; Nonrelevant Financial Relationships: Caris Life Sciences (spouse employment), Lymphoma Research Foundation. Dr Srinivas — Advisory Committees: Aveo Pharmaceuticals, Eisai Inc, Janssen Biotech Inc, Novartis, Seagen Inc; Contracted Research: Bristol Myers Squibb, Merck, Novartis, Regeneron Pharmaceuticals Inc; Data and Safety MonitoringBoard/Committee: Pfizer Inc. Dr Wander — Advisory Committees: Biovica International AB, Genentech, a member of the Roche Group, Hologic Inc, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics Group; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Foundation Medicine, Lilly, Novartis; Contracted Research: Genentech, a member of the Roche Group, Lilly, Nuvation Bio, Pfizer Inc, Regor Therapeutics Group, Sermonix Pharmaceuticals; Data and Safety Monitoring Board/Committee: Regor Therapeutics Group; Speakers Bureaus: Guardant Health, Lilly; Nonrelevant Financial Relationship: 2^nd.MD.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSeraTherapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME/NCPD Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Daiichi Sankyo Inc, Gilead Sciences Inc, Hologic Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Regeneron Pharmaceuticals Inc, and Stemline Therapeutics Inc.

The Ritz-Carlton Orlando, Grande Lakes
4012 Central Florida Parkway
Orlando, FL 32837
Hotel Phone: (407) 206-2400

Meeting Room
Tuscany Ballroom (Salons D-H) — Lobby Level

Hotel Room Reservations

• Florida Cancer Specialists (FCS) members, please be sure to book accommodations in the FCS room block.
•  
• For all other registrants, room reservation information will be included with the confirmation email after you have registered for this program.

 

Map: